奥曲肽联合经动脉插管化疗栓塞治疗伴肝硬化肝细胞癌 |
| |
引用本文: | 陆建勋,马亦龙,罗彪,LU Jian-xun,MA Yi-long,LUO Biao.奥曲肽联合经动脉插管化疗栓塞治疗伴肝硬化肝细胞癌[J].右江民族医学院学报,2009,31(1). |
| |
作者姓名: | 陆建勋 马亦龙 罗彪 LU Jian-xun MA Yi-long LUO Biao |
| |
作者单位: | 1. 右江民族医学院附属医院肿瘤科,广西,百色,533000 2. 广西医科大学附属肿瘤医院介入科,广西,南宁,530021 |
| |
摘 要: | 目的评价奥曲肽联合经动脉插管化疗栓塞(TACE)治疗伴肝硬化肝细胞癌的临床效果。方法选择Child-Pugh评分A或B级伴肝硬化肝细胞癌患者共55例。实验组24例,行TACE术后第1天开始使用奥曲肽0.2mg皮下注射,每天2次。对照组31例,接受TACE治疗。每3个月进行1次评价。对两组6个月及1、2、3年的生存率进行比较。结果两组均无CR,实验组中16例PR,有效率为66.67%。对照组中11例PR,有效率为35.48%。两组有效率差异有显著性(P<0.05)。实验组3年生存率为45.83%,而对照组3年生存率为19.35%。两组3年生存率差异有显著性(P<0.05)。实验组中位生存期为31个月,对照组中位生存期为20个月。实验组中位TTP为9个月,对照组为6个月。奥曲肽副作用主要为轻度腹泻。结论奥曲肽联合TACE治疗伴肝硬化肝细胞癌有明确的效果。
|
关 键 词: | 奥曲肽 肝硬化 肝细胞癌 化学栓塞 治疗性 |
Octreotide in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma associated with liver cirrhosis |
| |
Abstract: | Objective This article is to evaluate the effects of octreotide in combination with transcatheter arterial chemoembolization(TACE) for hepatocellular carcinoma complicated with liver cirrhosis.Methods Fifty-five consecutive patients in Child-Pugh classification A and B were admitted into the 3-year trial.Twenty-four patients in the octreotide group received octreotide 0.2mg IH twice a day following the treatment of TACE on day 1.Thirty-one patients received TACE alone were enrolled into the control group.The efficacy were assessed once every 3 months.A comparison of the 6-month、1-year、2-year and 3-year survival rate between the two groups were performed.Results No complete response was got in both groups.In the octreotide group,partial response(PR) was got in 16(66.67%) of the 24 patients,whereas in the control group,PR was achieved in 11(35.48%) of the 31 patients.There was statistical significant difference in response rate between the two groups(P<0.05).The 3-year overall survival rate of the octreotide group and the control group were 45.83% and 19.35%,respectively.There was statistical significant difference in 3-year overall survival rate between the two groups(P<0.05).The overall survival rate of the octreotide group was significantly higher than that of the control group(p < 0.05).The median survival of the octreotide group and the control group were 31 months and 20 months,respectively.The aliment development in the octreotide group was 9 months vs 6 months in the control group.The major complication of the octreotide treatment was mild diarrhea.Conclusion It was effective of octreotide in combination with TACE for hepatocellular carcinoma associated with liver cirrhosis. |
| |
Keywords: | Octreotide liver cirrhosis hepatocellular carcinoma chemoembolization therapeutic |
本文献已被 维普 万方数据 等数据库收录! |
|